Prostate Specific Membrane Antigen PET/CT Imaging in PSMA-Related Disease Patients
Recruiting now
Conditions studied: PSMA-related Disease, Prostate Cancer, Positron Emission Tomography, Metastasis, FAP
In brief
To evaluate the potential usefulness of 68Ga/18F-PSMA/PSFA positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various PSMA-related disease patients.
Key facts
- Study ID
- NCT06690970
- Run by
- Tianjin Medical University
- People needed
- 500
- Starts
- 2020-09-01
- Expected to finish
- 2027-12-01
- Last updated by the study team
- 2025-08-11
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled PSMA PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.
You may not qualify if…
- (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
Where it is running
- The First Affiliated Hospital of University of Science and Technology of China — Hefei, Anhui, China (enrolling)
- Tianjin Medical University General Hospital — Tianjin, Tianjin Municipality, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.